To the Editor, Higashi et al. [1] once again enlightened the importance of sarcopenia in oncological surgery patients. As the authors mentioned in the study, sarcopenia and visceral fat amount can be predictors for postoperative complications including mortality and morbidities like liver dysfunction. However, assessment of sarcopenia needs to be straightforward in such studies. The authors assessed sarcopenia by computerized tomography (CT) (L3 muscle index) based on the previous reports that this surrogate indicator yields successful estimation of whole-body skeletal muscle mass. Although muscle mass estimation with CT seems to be a valid approach, diagnosis of sarcopenia needs further consideration. Because, impaired muscle functions and strength which have gained significant importance in recent years are important components of sarcopenia. This was carefully highlighted by a consensus report from the European Working Group on Sarcopenia in Older People [2, 3] . Along with the muscle mass, the group addressed physical performance as assessed by gait speed, and grip strength measured by handheld dynamometer to be used in the decision making for sarcopenia. Thus, using only L3 muscle index would cause false distinction between presarcopenia and sarcopenia. Secondly, the fixed wide ranges
